Henry G. Grabowski | Scholars@Duke

Henry G. Grabowski
Professor Emeritus of Economics

Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has over one hundred peer reviewed articles analyzing the economics of pharmaceuticals and also several books and monograph publications. Professor Grabowski has testified several times before Congress on the issues of FDA regulation, health care reform, drug innovation and generic competition and vaccine policies. He has received numerous awards and professional recognition including a special issue of essays published in his honor in 2011 in the International Journal of the Economics of Business. He also has served as an advisor to various government and business organizations, including the National Academy of Sciences, the Institute of Medicine, the Office of Technology Assessment, the Federal Trade Commission, and the General Accounting Office. The US Congress has recognized the significant role that a paper he published with Duke colleagues David Ridley and Jeff Moe had in the passage of legislation that incentivized development of new therapies for neglected diseases through the creation of priority review vouchers.

Current Appointments & Affiliations

Professor Emeritus of Economics, Economics, Trinity College of Arts & Sciences 2009
Director of the Program in Pharmaceutical and Health Economics, Economics, Trinity College of Arts & Sciences 2019

Contact Information

314 Social Sciences, Durham, NC 27708
Box 90097, Durham, NC 27708-0097
grabow@econ.duke.edu (919) 660-1839
http://fds.duke.edu/db/aas/Economics/faculty/grabow/publications.html

Background
Education, Training, & Certifications
- Ph.D., Princeton University 1967
- M.A., Princeton University 1964
- B.S., Lehigh University 1962
Previous Appointments & Affiliations
- Professor with Tenure, Economics, Trinity College of Arts & Sciences 1976 - 2009
- Research Professor, Sanford School of Public Policy, Duke University 1991 - 2009
- Chairman, Economics, Trinity College of Arts & Sciences 1989 - 1992
- Associate Professor with Tenure, Economics, Trinity College of Arts & Sciences 1972 - 1976
Recognition
In the News
- OCT 6, 2015 Bloomberg
  
  Henry Grabowski comments: Drugmakers say Pacific trade agreement to stifle investment
- AUG 20, 2015 Triangle Business Journal
  
  How Duke Fuqua profs connect to a $350M pharma transaction
- JUN 4, 2014 The Hill
  
  Henry Grabowski: Regs and costs will bring a decade of limited biosimilars development in the U.S.
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Grabowski, Henry G., Zoya Marriott, Penka Kovacheva, and Andrew Elzinga. “One Year after the Launch of the First U.S. Biosimilar Drug: Lessons for the Future?,” August 9, 2017.
  - Grabowski, Henry, Carlos Brain, Anna Taub, and Rahul Guha. “Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes.” American Journal of Health Economics 3, no. 1 (February 2017): 33–59. https://doi.org/10.1162/ajhe_a_00066.
    Full Text
  - Grabowski, Henry, Genia Long, Richard Mortimer, and Ani Boyo. “Updated trends in US brand-name and generic drug competition.” Journal of Medical Economics 19, no. 9 (September 1, 2016): 836–44. https://doi.org/10.1080/13696998.2016.1176578.
    Full Text Open Access Copy
  - Grabowski, H. G., and R. L. Manning. “An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors.” International Journal of the Economics of Business 23, no. 2 (May 3, 2016): 149–66. https://doi.org/10.1080/13571516.2016.1182690.
    Full Text Open Access Copy
  - DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. “Innovation in the pharmaceutical industry: New estimates of R&D costs.” Journal of Health Economics 47 (May 2016): 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012.
    Full Text Open Access Copy
  - Grabowski, H. G., M. W. Skinner, P. A. H. Hoppe, R. Manning, R. Tachdjian, J. F. Crone, and S. J. Younger. “Risk-based decision making and ethical considerations in donor compensation for plassma-derived medicinal products.” Transfusion 00 (March 2016).
    Open Access Copy
  - Lietzan, Erika Fisher, and Henry G. Grabowski. “FDA Regulation of Biosimilars,” September 16, 2015.
  - DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. “The cost of drug development.” The New England Journal of Medicine 372, no. 20 (May 2015): 1972. https://doi.org/10.1056/nejmc1504317.
    Full Text Open Access Copy
  - Grabowski, Henry G., Joseph A. DiMasi, and Genia Long. “The roles of patents and research and development incentives in biopharmaceutical innovation.” Health Affairs (Project Hope) 34, no. 2 (February 2015): 302–10. https://doi.org/10.1377/hlthaff.2014.1047.
    Full Text Open Access Copy
  - Grabowski, Henry G., Rahul Guha, and Maria Salgado. “Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.” Health Affairs (Project Hope) 33, no. 6 (June 2014): 1048–57. https://doi.org/10.1377/hlthaff.2013.0862.
    Full Text Open Access Copy
  - Grabowski, Henry, Rahul Guha, and Maria Salgado. “Biosimilar competition: lessons from Europe.” Nature Reviews Drug Discovery 13, no. 2 (February 2014): 99–100. https://doi.org/10.1038/nrd4210.
    Full Text Open Access Copy
  - Grabowski, H. G., G. Long, and R. Mortimer. “Recent Trends in Brand-Name and Generic Drug Competition.” Journal of Medical Economics, 2013, 1–8.
    Open Access Copy
  - Grabowski, Henry, Tracy Lewis, Rahul Guha, Zoya Ivanova, Maria Salgado, and Sally Woodhouse. “Does generic entry always increase consumer welfare?” Food and Drug Law Journal 67, no. 3 (January 2012): 373–ii.
    Open Access Copy
  - Grabowski, Henry G., Margaret Kyle, Richard Mortimer, Genia Long, and Noam Kirson. “Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.” Health Affairs (Project Hope) 30, no. 11 (November 2011): 2157–66. https://doi.org/10.1377/hlthaff.2010.0270.
    Full Text Open Access Copy
  - Grabowski, Henry G. “The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal Reflection.” International Journal of the Economics of Business 18, no. 2 (July 2011): 161–76.
    Open Access Copy
  - Grabowski, Henry, D. V., Genia Long, and Richard Mortimer. “Implementation of the Biosimilar Pathway: Economic and Policy Issues.” Seton Hall Law Review 41, no. 2 (2011): 511–57.
    Open Access Copy
  - Grabowski, Henry, R. J., Genia Long, and Richard Mortimer. “Data Exclusivity for Biologics.” Nature Reviews Drug Discovery 10, no. 1 (January 2011): 15–16.
    Open Access Copy
  - Moe, Jeffrey, Henry Grabowski, and David Ridley. “FDA review vouchers.” The New England Journal of Medicine 360, no. 8 (February 2009): 837. https://doi.org/10.1056/nejmc086492.
    Full Text
  - Baker-Smith, Carissa M., Daniel K. Benjamin, Henry G. Grabowski, Elizabeth D. Reid, Barry Mangum, John V. Goldsmith, M Dianne Murphy, et al. “The economic returns of pediatric clinical trials of antihypertensive drugs.” Am Heart J 156, no. 4 (October 2008): 682–88. https://doi.org/10.1016/j.ahj.2008.05.001.
    Full Text Link to Item
  - Grabowski, Henry G. “Follow-on biologics: data exclusivity and the balance between innovation and competition.” Nature Reviews Drug Discovery 7, no. 6 (June 2008): 479–88.
    Open Access Copy
  - Grabowski, H., and Y. R. Wang. “Do faster food and drug administration drug reviews adversely affect patient safety? An analysis of the 1992 prescription drug user fee act.” Journal of Law and Economics 51, no. 2 (May 1, 2008): 377–406. https://doi.org/10.1086/589934.
    Full Text Open Access Copy
  - Dimasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski. “Misleading congress about drug development: Reply.” Journal of Health Politics, Policy and Law 33, no. 2 (April 2008): 319–24. https://doi.org/10.1215/03616878-2007-063.
    Full Text
  - DiMasi, J. A., and H. G. Grabowski. “Should the patent system for new medicines be abolished?” Clinical Pharmacology and Therapeutics 82, no. 5 (November 2007): 488–90. https://doi.org/10.1038/sj.clpt.6100393.
    Full Text Open Access Copy
  - Moe, Jeffrey L. “Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention.” Duke Department of Economics Working Papers, November 2007.
    Open Access Copy
  - DiMasi, J. A., and H. G. Grabowski. “In reply [2].” Journal of Clinical Oncology 25, no. 16 (June 1, 2007): 2331. https://doi.org/10.1200/JCO.2007.11.6020.
    Full Text
  - Dimasi, J. A., and H. G. Grabowski. “The cost of biopharmaceutical R&D: Is biotech different?” Managerial and Decision Economics 28, no. 4–5 (June 1, 2007): 469–79. https://doi.org/10.1002/mde.1360.
    Full Text Open Access Copy
  - Grabowski, H. G., D. B. Ridley, and K. A. Schulman. “Entry and competition in generic biologics.” Managerial and Decision Economics 28, no. 4–5 (June 1, 2007): 439–51. https://doi.org/10.1002/mde.1352.
    Full Text Open Access Copy
  - Grabowski, H. G., and M. Kyle. “Generic competition and market exclusivity periods in pharmaceuticals.” Managerial and Decision Economics 28, no. 4–5 (June 1, 2007): 491–502. https://doi.org/10.1002/mde.1356.
    Full Text Open Access Copy
  - Li, Jennifer S., Eric L. Eisenstein, Henry G. Grabowski, Elizabeth D. Reid, Barry Mangum, Kevin A. Schulman, John V. Goldsmith, M Dianne Murphy, Robert M. Califf, and Daniel K. Benjamin. “Economic return of clinical trials performed under the pediatric exclusivity program.” Jama 297, no. 5 (February 7, 2007): 480–88. https://doi.org/10.1001/jama.297.5.480.
    Full Text Open Access Copy Link to Item
  - DiMasi, Joseph A., and Henry G. Grabowski. “Economics of new oncology drug development.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 2 (January 2007): 209–16. https://doi.org/10.1200/jco.2006.09.0803.
    Full Text Open Access Copy
  - Gokcekus, O., M. Adams, H. Grabowski, and E. Tower. “How did the 2003 prescription drug re-importation bill pass the house?” Economics and Politics 18, no. 1 (March 1, 2006): 27–45. https://doi.org/10.1111/j.1468-0343.2006.00161.x.
    Full Text Open Access Copy
  - Grabowski, Henry G., and Y Richard Wang. “The quantity and quality of worldwide new drug introductions, 1982-2003.” Health Affairs (Project Hope) 25, no. 2 (March 2006): 452–60. https://doi.org/10.1377/hlthaff.25.2.452.
    Full Text Open Access Copy
  - Ridley, David B., Judith M. Kramer, Hugh H. Tilson, Henry G. Grabowski, and Kevin A. Schulman. “Spending on postapproval drug safety.” Health Aff (Millwood) 25, no. 2 (March 2006): 429–36. https://doi.org/10.1377/hlthaff.25.2.429.
    Full Text Open Access Copy Link to Item
  - Saha, Atanu, Atanu Grabowski, Henry, Howard Birnbaum, Paul Greenberg, and Oded Bizan. “Generic Competition in the U.S. Pharmaceutical Industry.” International Journal of the Economics of Business, February 2006.
    Open Access Copy
  - Cockburn, Iain, and Genia Long. “The Market for Follow-On Biologics: How Will It Evolve?” Health Affairs 25, no. 5 (2006): 1291–1301.
    Open Access Copy
  - Ridley, David B., Henry G. Grabowski, and Jeffrey L. Moe. “Developing drugs for developing countries.” Health Aff (Millwood) 25, no. 2 (2006): 313–24. https://doi.org/10.1377/hlthaff.25.2.313.
    Full Text Open Access Copy Link to Item
  - Light, Donald W., and Rebecca N. Warburton. “Extraordinary claims require extraordinary evidence.” Journal of Health Economics 24, no. 5 (September 2005): 1030–33. https://doi.org/10.1016/j.jhealeco.2005.07.001.
    Full Text
  - DiMasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski. “Setting the record straight on setting the record straight: Response to the Light and Warburton rejoinder.” Journal of Health Economics 24, no. 5 (September 2005): 1049–53. https://doi.org/10.1016/j.jhealeco.2005.07.004.
    Full Text Open Access Copy
  - DiMasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski. “Extraordinary claims require extraordinary evidence.” Journal of Health Economics 24, no. 5 (September 2005): 1034–44. https://doi.org/10.1016/j.jhealeco.2005.07.002.
    Full Text Open Access Copy
  - Grabowski, Henry G. “Encouraging the Development of New Vaccines.” Health Affairs 24, no. 3 (2005): 697–704.
    Open Access Copy
  - Light, D. W., R. N. Warburton, J. A. DiMasi, R. W. Hansen, and H. G. Grabowski. “Setting the record straight in the reply by DiMasi, Hansen and Grabowski.” Journal of Health Economics 24, no. 5 (January 1, 2005): 1045–48. https://doi.org/10.1016/j.jhealeco.2005.07.003.
    Full Text
  - Grabowski, Henry G. “Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures.” Pharmacoeconomics 22, suppl. 2 (2004): 15–24.
    Open Access Copy
  - DiMasi, J. A., H. G. Grabowski, and J. Vernon. “R&D costs and returns by therapeutic category.” Drug Information Journal 38, no. 3 (2004): 211–23. https://doi.org/10.1177/009286150403800301.
    Full Text Open Access Copy Link to Item
  - Grabowski, Henry G. “The Ripple Effects of a Restrictive Medicaid Formulary (editorial).” American Journal of Managed Care 9, no. 10 (October 2003): 648–49.
    Open Access Copy
  - DiMasi, Joseph A., Ronald W. Hansen, and Henry G. Grabowski. “The price of innovation: new estimates of drug development costs.” Journal of Health Economics 22, no. 2 (March 2003): 151–85. https://doi.org/10.1016/s0167-6296(02)00126-1.
    Full Text Open Access Copy
  - Grabowski, Henry G. “Patents and New Product Development in the Pharmaceutical and Biotechnology Industry.” The Georgetown Public Policy Review 8, no. 2 (March 2003): 7–23.
    Open Access Copy
  - Grabowski, Henry G. “Patents, Innovation and Access to New Pharmaceuticals.” Journal of International Economic Law, February 2002, 849–60.
    Open Access Copy
  - Grabowski, Henry, D. V., John Vernon, and Joe DiMasi. “Returns on R&D for 1990s New Drug Introductions.” Pharmacoeconomics 20, no. Supplement 3 (2002).
    Open Access Copy
  - Allen, J. R., C. J. Anthony, L. A. Bosco, L. B. Burke, P. J. Byrns, C. A. Casnoff, D. Clark, et al. “A framework for research and evaluation into the effects of managed care on the pharmaceutical marketplace: Excerpts from the final report.” Journal of Research in Pharmaceutical Economics 10, no. 4 (January 1, 2001): 235–63.
  - Grabowski, H. G., and J. M. Vernon. “Effective patent life in pharmaceuticals.” International Journal of Technology Management 19, no. 1 (January 1, 2000): 98–120. https://doi.org/10.1504/ijtm.2000.002803.
    Full Text
  - Grabowski, H. G., and J. Vernon. “The distribution of sales revenues from pharmaceutical innovation.” Pharmacoeconomics 18 Suppl 1 (January 2000): 21–32. https://doi.org/10.2165/00019053-200018001-00005.
    Full Text Open Access Copy
  - Grabowski, Henry, Margaret, and Margaret John Vernon. “Effective Patent Life in Pharmaceuticals.” International Journal of Technology Management 19, no. 1/2 (2000): 98–120.
    Open Access Copy
  - Grabowski, Henry, P. F., and P. F. John Vernon. “The Determinants of Pharmaceutical Research and Development Expenditures.” Journal of Evolutionary Economics 10 (2000): 201–15.
    Open Access Copy
  - Grabowski, Henry G. “The Role of Cost-Effectiveness Analysis in Managed Care Decisions.” Pharmacoeconomics 14,suppl. 1 (1998): 15–24.
    Open Access Copy
  - Frank Sloan, Henry G. “"The Impact of Cost-Effectiveness on Public and Private Policies in Health Care: An International Perspective".” Social Science & Medicine 45, no. 4 (August 1997).
  - Grabowski, Henry, Vernon, and C Daniel Mullins. “Pharmacy Benefit Management, Cost-Effectiveness Analysis and Drug Formulary Decisions.” Social Science & Medicine 45, no. 4 (August 1997): 535–44.
    Open Access Copy
  - Grabowski, Henry G. “The Effect of Pharmacoeconomics on Company Research and Development Decisions.” Pharmacoeconomics 11, no. 5 (May 1997): 389–97.
  - Sloan, F. A., and H. G. Grabowski. “The Impact of Cost-Effectiveness on Public and Private Policies in Health Care: An International Perspective: Introduction and overview.” Social Science and Medicine 45, no. 4 (1997): 505–10. https://doi.org/10.1016/S0277-9536(97)81010-6.
    Full Text
  - Sloan, F. A., and H. G. Grabowski. “Conclusions and implications.” Social Science and Medicine 45, no. 4 (January 1, 1997): 645–47. https://doi.org/10.1016/S0277-9536(97)81011-8.
    Full Text
  - Grabowski, Henry G. “Longer Patents for Increased Genetic Competition: The Waxman-Hatch Act After One Decade.” Pharmacoeconomics 10,Suppl. 2 (1996): 110–23.
    Open Access Copy
  - DiMasi, Joseph A., John Vernon, and John Grabowski, Henry. “R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry.” International Journal of the Economics of Business 2, no. 2 (1995): 201–19.
    Open Access Copy
  - DiMasi, Joseph, Ronald Hansen, and Louis Lasagna. “Research and Development Costs for New Drugs by Therapeutic Category: A Study of the U.S. Pharmaceutical Industry.” Pharmacoeconomics 7, no. 2 (1995): 152–69.
  - Grabowski, H. G., and J. M. Vernon. “Returns to R&D on new drug introductions in the 1980s.” Journal of Health Economics 13, no. 4 (December 1994): 383–406. https://doi.org/10.1016/0167-6296(94)90010-8.
    Full Text Open Access Copy
  - Grabowski, Henry G. “Health Reform and Pharmaceutical Innovation.” Seton Hall Law Review 24, no. 3 (1994): 1221–59.
    Open Access Copy
  - Grabowski, Henry, Vernon, and Vernon John Vernon. “Innovation and Structural Change in Pharmaceuticals and Biotechnology.” Industrial and Corporate Change 3, no. 2 (1994): 435–49.
    Open Access Copy
  - Grabowski, Henry G., and John M. Vernon. “Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act.” The Journal of Law and Economics 35, no. 2 (October 1992): 331–50. https://doi.org/10.1086/467257.
    Full Text Open Access Copy
  - Grabowski, Henry G. “The Costs and Returns to Pharmaceutical Research and Development.” Revista Internazionale Di Scienze Sociali (International Social Studies Review), September 1992, 347–58.
    Open Access Copy
  - Grabowski, H. G., S. O. Schweitzer, and S. R. Shiota. “The effect of Medicaid formularies on the availability of new drugs.” Pharmacoeconomics 1, no. Suppl 1 (January 1992): 32–40. https://doi.org/10.2165/00019053-199200011-00009.
    Full Text
  - DiMasi, J. A., R. W. Hansen, H. G. Grabowski, and L. Lasagna. “Cost of innovation in the pharmaceutical industry.” Journal of Health Economics 10, no. 2 (July 1991): 107–42. https://doi.org/10.1016/0167-6296(91)90001-4.
    Full Text Open Access Copy
  - Grabowski, Henry G., and John Vernon. “A New Look at the Returns and Risks to Pharmaceutical R & D,” July 1990.
    Open Access Copy
  - Grabowski, Henry, F. J., and F. J. John Vernon. “A New Look at the Returns and Risks to Pharmaceutical R & D.” Management Science 36, no. 7 (July 1990): 804–21.
    Open Access Copy
  - Grabowski, Henry, Mueller, W Kip Viscusi, and William N. Evans. “Price and Availability Tradeoffs of Automobile Insurance Regulation.” Journal of Risk and Insurance LVI, no. 2 (June 1989): 275–99.
    Open Access Copy
  - GRABOWSKI, H. G. “AN ANALYSIS OF UNITED-STATES INTERNATIONAL COMPETITIVENESS IN PHARMACEUTICALS.” Managerial and Decision Economics, March 1, 1989, 27–33.
    Open Access Copy Link to Item
  - Grabowski, Henry G. “Medicaid Patients' Access to New Drugs.” Health Affairs, December 1988, 102–14.
    Open Access Copy
  - Grabowski, Henry G., and John M. Vernon. “Pioneers, Imitators, and Generics--A Simulation Model of Schumpeterian Competition.” The Quarterly Journal of Economics 102, no. 3 (August 1987): 491–491. https://doi.org/10.2307/1884215.
    Full Text Open Access Copy
  - Grabowski, Henry G. “The Health/Economic Benefits of Drug Therapy: Efficacy, Low Risk, Cost Effectiveness, Patient Information and Emancipation.” Swiss Pharma 9, no. 3a (1987): 29–31.
  - John Vernon, P. G. “Longer Patents for Lower Imitation Barriers: The 1984 Drug Act.” The American Economic Review 76, no. 2 (May 1986): 195–98.
    Open Access Copy
  - Grabowski, H. G. “Issues of drug development: orphan drugs.” Science (New York, N.Y.) 228, no. 4702 (May 1985): 981. https://doi.org/10.1126/science.228.4702.981.
    Full Text
  - Gort, Michael, and Robert McGuckin. “Organizational Capital and the Choice between Specialization and Diversification.” Managerial and Decision Economics 6, no. 1 (March 1985): 2–10.
  - Grabowski, H. G. “The Impact of Patent and Regulatory Policies on Drug Innovation.” Medical Marketing & Media 18, no. 10 (October 1983): 42–63.
  - Grabowski, Henry G. “Public Policy and Pharmaceutical Innovation.” Health Care Financing Review 4, no. 1 (September 1982): 75–87.
  - John Vernon, Mueller. “A Sensitivity Analysis of Expected Profitability of Pharmaceutical Research and Development.” Managerial and Decision Economics 3, no. 1 (March 1982): 36–40.
    Open Access Copy
  - Grabowski, Henry G. “Public Policy and Innovation: The Case of Pharmaceuticals.” Technovation 1 (1982): 157–89.
  - Arnould, Richard J. “Auto Safety Regulation: An Analysis of Market Failure.” The Bell Journal of Economics 12, no. 1 (March 1981): 27–48.
  - GRABOWSKI, H. G., and J. M. VERNON. “SUBSTITUTION LAWS AND INNOVATION IN THE PHARMACEUTICAL-INDUSTRY.” Law and Contemporary Problems 43, no. 1 (January 1, 1979): 43–66.
    Open Access Copy Link to Item
  - Grabowski, Henry G., and John M. Vernon. “SUBSTITUTION LAWS AND INNOVATION IN THE PHARMACEUTICAL-INDUSTRY,” 1979.
    Open Access Copy
  - GRABOWSKI, H. G. “IMPACT OF REGULATION ON INNOVATION.” Food and Drug Law Journal 34, no. 10 (January 1, 1979): 555–60.
    Link to Item
  - Grabowski, Henry G. “The Effects of Advertising on IntraIndustry Shifts on Demand.” Occasional Papers of the National Bureau of Economic Research, Explorations in Economic Research 4, no. 5 (October 1978): 675–701.
  - GRABOWSKI, H. G. “EFFECTS OF SUBSTITUTION LAWS ON INNOVATION.” Drug Therapy 8, no. 12 (January 1, 1978): 91.
    Link to Item
  - Grabowski, H. G., J. M. Vernon, and L. G. Thomas. “Estimating the effects of regulation on innovation: an international comparative analysis of the pharmaceutical industry.” The Journal of Law & Economics 21, no. 1 (January 1978): 133–63. https://doi.org/10.1086/466914.
    Full Text Open Access Copy
  - Grabowski, H. G., and J. M. Vernon. “Consumer product safety regulation.” American Economic Review 68, no. 2 (January 1, 1978): 284–89.
  - Grabowski, Henry G., Lacy Glenn Thomas, and John M. Vernon. “Estimating the effects of regulation on innovation: an international comparative analysis of the pharmaceutical industry.,” 1978.
    Open Access Copy
  - Grabowski, Henry G., and Dennis C. Mueller. “Industrial Research and Development, Intangible Capital Stocks, and Firm Profit Rates.” The Bell Journal of Economics 9, no. 2 (1978): 328–328. https://doi.org/10.2307/3003585.
    Full Text
  - GRABOWSKI, H. G., and J. M. VERNON. “CONSUMER-PROTECTION REGULATION IN ETHICAL DRUGS.” American Economic Review 67, no. 1 (January 1, 1977): 359–64.
    Open Access Copy Link to Item
  - Grabowski, Henry G., and Dennis C. Mueller. “Life-Cycle Effects on Corporate Returns on Retentions.” The Review of Economics and Statistics 57, no. 4 (November 1975): 400–400. https://doi.org/10.2307/1935899.
    Full Text
  - Baxter, Nevins D. “Rivalry in Research and Development: An Empirical Study.” Journal of Industrial Economics 21, no. 2 (July 1973): 209–35.
  - Corazzani, A., D. Dugan, and D. Grabowski, Henry. “Determinants and Distributional Aspects of Enrollment in U.S. Higher Education.” Journal of Human Resources 7, no. 1 (December 1972): 39–59.
    Open Access Copy
  - Grabowski, Henry, J. D., and J. D. Dennis Mueller. “Managerial and Stockholder Welfare Models of Firm Expenditures.” Review of Economics and Statistics 54 (February 1972): 9–24.
    Open Access Copy
  - Dennis Mueller, H. G. “Imitative Advertising in the Cigarette Industry.” The Journal of American and Foreign Antitrust and Trade Regulations 16, no. 2 (July 1971): 257–92.
  - Dennis Mueller, H. G. “Non-Price Competition in the Cigarette Industry: A Coment.” Antitrust Bulletin 40 (December 1970): 257–92.
  - Grabowski, Henry G. “Demand Shifting, Optimal Firm Growth, and Rule-of-Thumb Decision Making.” Quarterly Journal of Econoics 84 (May 1970): 217–35.
    Open Access Copy
  - Dennis Mueller, A. “Industrial Organization: The Role and Contribution of Econometrics.” American Economic Review 60, no. 2 (May 1970): 100–104.
    Open Access Copy
  - Grabowski, Henry G. “The Determinents of Industrial Research and Development: A study of the chemical, drug, and petrolium industries,” 1968.
    Open Access Copy
  - Grabowski, Henry G. “The Determinents of Industrial Research and Development: A study of the chemical, drug, and petrolium industries.” Journal of Political Economy 76, no. 2 (1968): 292–306.
    Open Access Copy
- Book Sections
  - Grabowski, H. G. “FDA in the Twenty-First Century.” In FDA Regulation Of Biosimilars, edited by G. Cohen, and H. Lynch, 414–30. Columbia University Press, 2015.
    Open Access Copy
  - Grabowski, H. G., G. Long, and R. Mortiner. “Biosimilars.” In Encyclopedia of Health Economics, edited by A. Culyer, Vol. 1. Elsevier, 2014.
  - Grabowski, H. G. “The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982-2003.” In Incentives for Research, Development, and Innovation in Pharmaceuticals, edited by Walter A. Garcia-Fontes, 49–68. Springer, 2012.
    Open Access Copy
  - Grabowski, H. G. “Mergers, Accquisitions, and Alliances.” In The Oxford Handbook of the Economics of the Biopharmaceutical Industry, edited by Patricia M. Danzon and Sean Nicholson, 552–77. New York, NY: OUP USA, 2012.
    Open Access Copy
  - DiMasi, Joseph A., T. A. E., and H. G. Grabowski. “R&D Costs and Returns to New Drug Develoopment: A Review of the Evidence.” In The Oxford Handbook of the Economics of the Biopharmaceutical Industry, edited by Patricia M. Danzon and Sean Nicholson, 22–46. New York, NY: OUP USA, 2012.
    Open Access Copy
  - Grabowski, H. G., H. G. Ridley, David B., and H. G. Moe, Jeffrey L. “Encouraging innovative treatment of neglected diseases through priority review vouchers.” In Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, edited by Karen Eggleston, 347–65. Stanford, CA: Stanford University: The Walter H, Shorenstein Asia-Pacific Research Center, 2009.
    Open Access Copy
  - Grabowski, H. G., and Margaret Kyle. “Mergers and Alliances in Pharmaceutical: Effects on Innovation and R&D Productivity.” In The Economics of Corporate Governance and Mergers, edited by K. Gugler and B. Yurtoglu, 262–87. Cheltenham, UK; USA: Edward Elgar Publishing, 2008.
    Open Access Copy
  - Grabowski, H. G. “Competition between Generic and Branded Drugs.” In Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective, edited by Frank A. Sloan and Chee-Ruey Hsieh, 153–288. Cambridge; New York: Cambridge University Press, 2007.
    Open Access Copy
  - Grabowski, H. G. “Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act.” In International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, edited by Keith Keith Eugene Maskus and J Jerome H. Reichman, 457–80, 2005.
    Open Access Copy
  - Grabowski, H. G. “Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act.” In International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, edited by Keith Keith Eugene Maskus and J Jerome H. Reichman, 457–80. Cambridge, UK, New York: Cambridge University Press, 2005.
    Open Access Copy
  - Grabowski, H. G., and H. G. Vernon, John. “Pressures from the Demand Side: Changing Market Dynamics and Industrial Structure.” In Consolidation and Competition in the Pharmaceutical Industry, edited by Hannah E. Kettler, 62–79. London, UK: Office of Health Economics, 2001.
    Open Access Copy
  - Grabowski, H. G. “Public Policy and Innovation in Pharmaceuticals and Biotechnology.” In Business and Economics for the 21st Century Volume 1, edited by D. Kantarelis, 1:343–49. Worcester, MA: Business and Economic Society International, 1997.
  - Grabowski, H. G. “'Price and Profit Control, New Competitive Dynamics and the Economics of Innovation in the Pharmaceutical Industry'.” In Industrial Policy and the Pharmaceutical Industry, edited by Adrian Towse, 77–91. London: Office of Health Economics, 1995.
    Open Access Copy
  - Zarkin, Gary A., Hernando, H. G. Grabowski, H. G. Mauskopf, Josephine, H. G. Bannerman, Heather A., and H. G. Weisler, Ricard H. “Economic Evaluation of Drug Treatment for Psychiatric Disorders: The New Clinical Trial Protocol.” In Psychopharmacology: The Fourth Generation of Progress, edited by Floyd E. Bloom and David J Kupfer ed, 1897–1905. New York, NY: Raven Press, 1995.
    Open Access Copy
  - Grabowski, H. G. “Product Liability in Pharmaceuticals: Comments on Chapters Eight and Nine.” In The Liability Maze: The Impact of Liability Law on Safety and Innovation, edited by Peter Peter William Huber and Robert E. Litan, 360–66. Washington DC: The Brookings Institution Press, 1991.
    Open Access Copy
  - Grabowski, H. G. “The Changing Economics of Pharmaceutical Research and Development.” In The Changing Economics of Medical Technology, edited by H. G. Gelijns, Annetine C. and H. G. Halm, Ethan A., 35–52. Washington, DC: National Academies Press, 1991.
    Open Access Copy
  - Grabowski, H. G. “Innovation and International Competitiveness in Pharmaceuticals.” In Evolving Technology and Market Structure: Studies in Schumpeterian Economics, edited by H. G. Heertje, Arnold and H. G. Perlman, Mark, 167–85. Ann Arbor, MI: University of Michigan Press, 1990.
    Open Access Copy
  - Grabowski, H. G., and H. G. Vernon, John. “A Computer Simulation Model of Pharmaceutical Innovation.” In Pharmaceutical Economics, edited by H. G. Lindgren, Bjorn, 159–75. Lund, Sweden: Swedish Institute for Health Economics and Liber Forlag, 1984.
    Open Access Copy
  - Grabowski, H. G., and John Vernon. “A Computer Simulation Model of Pharmaceutical Innovation.” In Pharmaceutical Economics: Papers Presented at the 6. Arne Ryde Symposium, Helsingborg, Sweden 1982, edited by Björn Lindgren, 159–75. Malmö, Sweden: Swedish Institute for Health Economics and Liber Forlag, 1984.
    Open Access Copy
  - Grabowski, H. G., and H. G. Vernon, John. “The Pharmaceutical Industry.” In Government and Technical Progress, edited by Richard R. Nelson and New York University Graduate School of Business Administration Center for Science and Technology Policy, 283–360. New York, NY: Pergamon, 1982.
    Open Access Copy
  - Grabowski, Henry G., and John M. Vernon. “The Pharmaceutical Industry.” Pergamon, 1982.
    Open Access Copy
  - Grabowski, H. G., H. G. Vernon, John, and H. G. Thomas, Lacy Glenn. “Impact of Public Policy on Drug Innovation and Pricing.” In Impact of Public Policy on Drug Innovation and Pricing, edited by Samuel A. Mitchell and Emery Link. Washington, DC: American University, 1976.
    Open Access Copy
  - Grabowski, H. G., and H. G. Vernon, John M. “Structural Effects of Regulation on Innovation in the Ethical Drug Industry.” In Essays on Industrial Organization, in Honor of Joe S. Bain, edited by Joe Staten Bain, Robert T. Masson, and P David Qualls, 181–205. Cambridge, MA: Ballinger Publishing Company, 1976.
    Open Access Copy
  - Grabowski, H. G. “Graph-Oriented Model for Research Management.” In Research Program Effectiveness. Proceedings of the Conference Sponsored by the Office of Naval Research, Washington, D.C., July 27-29, 1965. Edited by M. C. Yovits [and Others], Etc, edited by Marshall Clinton YOVITS, Marshall Clinton Gilford, D.M., Marshall Clinton Staveley, E., and Marshall Clinton Lerner, H.D., 187–216. New York, NY: Gordon and Breach, 1966.
    Open Access Copy
- Journal Issues
  - Sloan, F. A., and H. Grabowski, eds. “The Impact of Cost-Effectiveness on Public and Private Policies in Health Care: An International Perspective.” Social Science and Medicine. Pergamon Press Ltd., August 1997.
    Link to Item
- Conference Papers
  - Grabowski, H. G. “Pharmaceuticals and Health Care Costs,” n.d.
    Open Access Copy

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

In the News

Selected Publications

Academic Articles

Book Sections

Journal Issues

Conference Papers